Trends in PCSK9 inhibitor utilization in the United States, Europe, and other countries: An analysis of international sales data
Open accessThe claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The better implementation and persistence in European populations compared with the United States is likely attributable to health care system accessibility, cost-sharing structures, study design, and medication monitoring practices.
“likely attributable to health care system accessibility, cost-sharing structures, study design, and medication monitoring practices.119, 120, 121, 122, 123”
From Adherence to PCSK9 Inhibitors in Clinical Practice (2026) · cites this paper as [121]
The Discussion links differences in PCSK9 inhibitor utilization to access and countries’ ability to pay. It does not assess whether European patients have better implementation or persistence than US patients, or attribute such a difference to cost-sharing, study design, or medication monitoring. The Limitations state that individual-level data and patients’ out-of-pocket costs were unavailable. (LLM, conf=0.78)
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
No references could be resolved yet.
Research works printed but not linked: 13
- PCSK9 inhibitor monoclonal antibodies for the treatment of hypercholesterolemia. CADTH issues in emerging health technologies; issue 145 [Internet]. Vol. 2015 Dec. Ottawa, Canada: CADTH; 2015 [cited 2021 May 10]. Available from: https://www.cadth.ca/dv/ieht/pcsk9-inhibitor-monoclonal-antibodies-treatment- hypercholesterolemia
- Shrank WH, Lotvin A, Singh S, Brennan T. In the debate about cost and efficacy, PCSK9 inhibitors may be the biggest challenge yet. Health Affairs Blog [Internet]. 2015; Available from: https://www.healthaffairs.org/do/10.1377/hblog20150217.044597/full/ · DOI
- PCSK9 inhibitors for treatment of high cholesterol: Effectiveness, value, and value-based price benchmarks [Internet]. Institute for Clinical and Economic Review; 2015 Nov [cited 2021 May 10]. Available from: https://icer.org/assessment/high- cholesterol-2015/
- Broder MS, Zambrano JM, Lee J, Marken RS. Systematic bias in predictions of new drugs' budget impact: Analysis of a sample of recent US drug launches. Curr Med Res Opin [Internet]. 2018;34(5):765-73. Available from: https://doi.org/10.1080/03007995.2017.1320276 · DOI
- Yan VKC, Blais JE, Li X, Chui CSL, Wei L, Yan BP, et al. Trends in cardiovascular medicine use in 65 middle-and high-income countries. J Am Coll Cardiol. 2021;77(7):1021-3.
- Attipoe-Dorcoo S, Yang P, Sperling L, Loustalot F, Thompson-Paul AM, Gray EB, et al. Characteristics and trends of PCSK9 inhibitor prescription fills in the United States. J Clin Lipidol [Internet]. 2021; Available from: https://doi.org/10.1016/j.jacl.2021.01.010 · DOI
- Sumarsono A, Lalani HS, Vaduganathan M, Navar AM, Fonarow GC, Das SR, et al. Trends in utilization and cost of low-density lipoprotein cholesterol-lowering therapies among Medicare beneficiaries: An analysis from the Medicare Part D database. JAMA Cardiol. 2021;6(1):92-6.
- IQVIA. 2019 accuracy and timeliness statistics (ACTS) annual report [Internet]. 2020 [cited 2021 Apr 10]. Available from: https://www.iqvia.com/library/publications/acts-2019-33rd-edition-quality-assurance- report-of-iqvia
- Kanavos P, Ferrario A, Vandoros S, Anderson GF. Higher US branded drug prices and spending compared to other countries may stem partly from quick uptake of new drugs. Health Aff (Millwood) [Internet]. 2013;32(4):753-61. Available from: https://www.healthaffairs.org/doi/abs/10.1377/hlthaff.2012.0920 · DOI
- Wysowski DK, Kennedy DL, Gross TP. Prescribed use of cholesterol-lowering drugs in the United States, 1978 through 1988. JAMA [Internet]. 1990;263(16):2185- 8. Available from: https://doi.org/10.1001/jama.1990.03440160047035 · DOI
- Jackevicius CA, Tu JV, Ross JS, Ko DT, Krumholz HM. Use of ezetimibe in the United States and Canada. N Engl J Med. 2008;358(17):1819-28.
- Blais JE, Wei Y, Yap KKW, Alwafi H, Ma TT, Brauer R, et al. Trends in lipid- modifying agent use in 83 countries. Atherosclerosis [Internet]. 2021;328:44-51. Available from: https://www.ncbi.nlm.nih.gov/pubmed/34091069 References
- Kanavos P, Mossialos E. International comparisons of health care expenditures: what we know and what we do not know. J Health Serv Res Policy. 1999;4(2):122-6.
Cited by
Sorted by citations
Adherence to PCSK9 Inhibitors in Clinical Practice
Blais, J. E., Zhong, W., Li, C. Y. V., Kongkaew, C., & Chan, A. H. Y. (2026) · JACC: Advances · doi:10.1016/j.jacadv.2026.102733 · Cited by 7 · see citing works
Self-citation
- Authors
- Blais, J. E., Wei, Y., Knapp, M., Wong, I. C. K., Wei, L., & Chan, E. W.
- Affiliations
- University of Hong Kong (HK)
- London School of Economics and Political Science (GB)
- Laboratory of Data Discovery for Health (HK)
- University of Hong Kong - Shenzhen Hospital (CN)
- Corresponding author
- Chan, Esther W.
- Venue
- American Heart Journal
- Publisher
- Elsevier BV
- Published
- 2022-06
- Volume
- 248
- Pages
- 13-20
- ISSN
- 0002-8703 (ISSN-L)
- OpenAlex
- W4214510543
- Cited by
- 16
- References
- 0
- Citations by year
- 2026: 5 · 2025: 4 · 2024: 2 · 2023: 3 · 2022: 2
- FWCI
- 2.64
- Type
- journal article
- Language
- en
- Open access
- green
- discovery.ucl.ac.uk
- Locations
- American Heart Journal (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Funders
- Amgen
- Research Grants Council, University Grants Committee
- Topics
- Health Sciences › Medicine › Surgery › Lipoproteins and Cardiovascular Health
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
- Health Sciences › Medicine › Surgery › Coronary Interventions and Diagnostics
- Keywords
- PCSK9 inhibitors, drug use trends, lipid-lowering therapy, hypercholesterolemia, drug adoption
- MeSH terms
- PCSK9 Inhibitors, Hypolipidemic Agents, Commerce, Europe, Humans, United States
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
